LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026 and will participate in a fireside chat on March 3, 2026 at 10:30am ET. A live audio webcast of this event will be accessible from the "Events†page of the Investors section of the C ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares ("ADSs†) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre- funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999. ...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 million of American Depositary Shares ("ADSs†), each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase ADSs. All securities are being offered by Compass Pathways. Compass Pathways expe ...

Core Insights - Compass Pathways has made significant progress in its psilocybin therapy for treatment-resistant depression (TRD), achieving positive results in two Phase 3 trials and planning to submit a New Drug Application (NDA) to the FDA [2][5][6] Group 1: Clinical Trial Results - The second Phase 3 trial met its primary endpoint, demonstrating statistically significant results for the proprietary formulation COMP360 [5] - The trials involved over 1,000 participants, showcasing consistent and clinically meaningful effects, which is a notable achievement in the challenging field of TRD treatment [5] Group 2: Market Reaction - Following the announcement of the trial results, Compass Pathways' stock surged by over 50%, with a trading increase of 42.3% noted shortly after the news [3][6] - The positive trial outcomes have prompted investor interest, indicating a potential for continued stock growth pending FDA feedback [6] Group 3: Regulatory Steps - Compass has requested a meeting with the FDA and aims to submit the NDA for full approval by the end of the year, marking a critical step in the drug approval process [6]

Core Insights - Compass Pathways plc has successfully achieved the primary endpoint in the ongoing Phase 3 COMP006 trial, which is the second of two Phase 3 trials evaluating COMP360 for treatment-resistant depression [1] Group 1 - The trial is assessing two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin [1] - The primary endpoint focused on the difference in change, indicating a significant milestone in the trial's progress [1]

To add Benzinga News as your preferred source on Google, click here .Here are some other stocks moving in pre-market trading.Shares of ZIM Integrated Shipping Services Ltd (NYSE:ZIM) rose sharply in pre-market trading after the company agreed to be acquired by Hapag-Lloyd for $35.00 per share in cash at aggregate cash consideration of approximately $4.2 billion. ...

Core Insights - Compass Pathways plc is set to report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic formulation of psilocybin for treatment-resistant depression (TRD) [1] Group 1 - The company will disclose new clinical data from Part A and Part B of trial COMP005 and Part A of trial COMP006 [1]

Core Insights - Compass Pathways plc has received FDA acceptance for its IND application for COMP360, allowing the start of a late-stage clinical trial for PTSD [1][5] - The company aims to address the significant unmet need in PTSD and treatment-resistant depression (TRD) through innovative therapies [2][14] Late-Stage Clinical Trial for PTSD - The Phase 2b/3 clinical trial (COMP202) will evaluate the efficacy, safety, and tolerability of COMP360 in PTSD patients [5] - The trial consists of two parts: a 12-week blinded study comparing two doses of COMP360 (25 mg vs. 1 mg) and a 40-week open-label follow-up [5] - The primary efficacy endpoint is the change in CAPS-5 total severity score at Week 8 [5] Commercialization Readiness in TRD - Compass is preparing for the commercialization of COMP360 for TRD, with a focus on ensuring patient access if approved [2][12] - The company has had positive discussions with the FDA regarding its NDA submission strategy for COMP360 in TRD, including potential rolling submission scenarios [5] - The company has also expanded its collaborations to enhance the integration of COMP360 into healthcare settings [5] Financial Updates - Compass has amended its term loan facility with Hercules Capital, increasing it to $150 million, with $50 million already drawn [12] - The amendment extends the interest-only period until at least January 2029, providing financial flexibility [12] About PTSD and TRD - PTSD affects approximately 13 million adults in the U.S. annually, with limited treatment options available [10][8] - TRD impacts around 4 million patients in the U.S., characterized by inadequate response to multiple treatments [13]

Core Viewpoint - Compass Pathways plc is entering its seventh strategic collaboration with Radial Health, Inc. to enhance patient access to evidence-based innovation in interventional psychiatry [1] Group 1: Company Overview - Compass Pathways plc is a biotechnology company focused on accelerating patient access to innovative treatments [1] - Radial Health, Inc. is a national network specializing in interventional psychiatry practices, utilizing technology and operational expertise [1] Group 2: Strategic Collaboration - The collaboration aims to inform the development of scalable delivery models for psychiatric care [1]

Company Overview - COMPASS Pathways plc (NASDAQ:CMPS) is a London-based biotechnology company founded in 2020, focusing on mental health and committed to mental well-being [5]. Investment Potential - COMPASS Pathways is considered one of the best stocks for quick wealth accumulation, with a majority of analysts giving it a 'Buy' or equivalent rating. The median price target is $15, indicating an upside potential of 119.14% from the current price [1]. - Oppenheimer upgraded COMPASS Pathways to 'Outperform' from 'Perform', setting a price target of $15, driven by the potential of its psilocybin therapy for treatment-resistant depression [3]. - Gavin Clark-Gartner from Evercore ISI reaffirmed a 'Hold' rating with a price target of $8, reflecting a 16.87% upside potential from the current level [2]. Market Opportunity - Oppenheimer estimates a record sales opportunity of nearly $1.5 billion for COMPASS Pathways' psilocybin-based therapy, COMP360, which is significant compared to the company's current market capitalization of over $600 million [4]. - The company is expected to benefit from an early-mover advantage in the psychedelics space, supported by a strong financial position and adequate cash runway [4].